1 / 15

Erlotinib Plus Gemcitabine Compared to Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer An exploratory

. . . . Patient PopulationAdenocarcinoma of pancreasNo prior chemotherapyMeasurable or non-measurable diseaseEGFR status not an eligibility criterionStratification Center PS (0/1 vs 2) Stage of disease (Loc Adv / Metastatic). RANDOM I ZE. Gemcitabine 1000 mg/m2 over 30 minutes weekly

hart
Télécharger la présentation

Erlotinib Plus Gemcitabine Compared to Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer An exploratory

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    More Related